Drug Trial Radar · NCT04529850
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Aug 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 30, 2020
Primary completion
Mar 10, 2021
Study completion Mar 10, 2021
Sponsor
- Lead sponsor
- Galera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 (IV) when administered in combination with IMRT and cisplatin to up to subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)
Conditions
- Head and Neck Cancer
- Oral Mucositis
Interventions
Drug: GC4419Drug
GC4419 60 Minute Infusion
Intensity-modulated radiation therapy (IMRT)Radiation
2.0 to 2.2 Gy daily over 7 weeks
CisplatinDrug
100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent AE'sTime frame: First dose of study medication through the 30 days following the last dose of IMRT, GC4419, or cisplatin (whichever occurs last) which is estimated to be 11 weeks
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst
Aalst, Belgium
AZ Klina
Brasschaat, Belgium
Az Nikolaas
Sint-Niklaas, Belgium
CHR Verviers
Verviers, Belgium
Fakultni Nemocnice Na Bulovce
Prague, Czechia
University Medical Center Schleswig-Holstein
Kiel, Germany
Universitatsklinikum Leipzig AoR
Leipzig, Germany
Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy
Bydgoszcz, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
Krakow, Poland
Szpitale Pomorskie Sp. z o.o.
Pomorskie, Poland
Cancer Center Institute of Oncology
Warsaw, Poland
Complejo Hospitalario Universitario De Santiago De Compostela
A Coruña, Spain
Gurutzetako Unibersitate Ospitalea - Hospital Universitario Cruces - Instituto BioCruces
Barakaldo, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Fuenlabrada
Fuenlabrada, Spain
Institut Catala d'Oncologia de Girona
Girona, Spain
Complejo Hospitalario de Jaen
Jaén, Spain
Hospital Madrid Universitario Sanchinarro (Centro Integral Oncologico Clara Campal)
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Complejo Hospitalario de Navarra (CHN)
Pamplona, Spain
Hospital universitario Virgen del Rocio
Salamanca, Spain
Universidad de Salamanca - Hospital Clinico Universitario
Salamanca, Spain
University Hospital Basel
Basel, Switzerland
University Hospital of Bern, Inselspital
Fribourg, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.